YH-16联合MVP方案治疗晚期非小细胞肺癌的临床观察

Clinical observation of YH-16 plus MVP scheme in advanced non-small cell lung cancer

目的观察重组人血管内皮抑素(-16)联合丝裂霉素、长春新碱和顺铂(MVP)治疗ⅢB-Ⅳ期非小细胞肺癌(NSCLC)的近期临床疗效和安全性。评价治疗前、后外周血检测癌胚抗原(CEA)在NSCLC治疗中的应用价值。方法应用-16联合MVP方案治疗晚期NSCLC 33例,检测治疗前、后外周血CEA数量。结果 33例患者临床有效率12%(4/33),临床收益率58%(19/33)。33例患者血清CEA水平治疗前(49.64±4.17)ng/ml下降到第2周期治疗后(14.88±1.13)ng/ml,两组CEA水平相比(P<0.05),差异有统计学意义。结论 -16联合MVP方案治疗晚期NSCLC是合理、安全及有效。CEA可能是一个较好的预测化疗联合抗肿瘤血管生成治疗疗效的标志。

Objective To discuss the short efficacy and safety of recombinant human rh - endostatin（YH - 16） plus mitomycin ＋ vincristine sulfate ＋ cisplatinum （MVP） programme in the treatment of stage ⅢB-Ⅳ non - small cell lung cancer （ NSCLC ）, and to investigate the changes and clinical valua of carcino - embryonic antigen （CEA） in the peripheral blood of advanced NSCLC. Methods Thirty - three patients with advanced NSCLC were treated by YH - 16 plus MVP proposal. Level of CEA in the peripheral hlood were measured. Results Thirty - three patients clinical efficiency was 12% （4/33）and clinical benefit rate was 58% （ 19/33 ）. The number of CEA decreased from（ 49. 64 ~ 4. 17 ）ng/ml to（ 14. 88 ±1.13 ） ng/ml in thirty - three patients. Conclusions YH - 16 plus MVP programme were effective, reasonable, safe for advanced NSCLC. CEA may be useful in predicting the efficacy of the combined treatment.